Allergen Immunotherapy for the Prevention and Treatment of Asthma
Clinical & Experimental Allergy · 2025-02 · 55 (2) · 111-141
DOI: 10.1111/cea.14575 ↗At a glance
Übersichtsarbeit in Clinical & Experimental Allergy, published online on 2024-10-04. Written by Thierry Batard and 9 co-authors. Institution: Innovation & Science Department, Stallergenes Greer, Antony, France. Major MEDLINE topics: Asthma, Desensitization, Immunologic, Allergens. Cited 33 times so far (Crossref); 142 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Stallergenes Greer.
Abstract (original language)
Allergic asthma is the predominant phenotype among asthmatics. Although conventional pharmacotherapy is a central component in the management of asthma, it does not enable control of asthma symptoms in all patients. In recent decades, some uncontrolled asthmatic patients, especially those with allergic asthma, have benefited from biological therapies. However, biologics do not address all the unmet needs left by conventional pharmacotherapy. Furthermore, it is noteworthy that neither conventional pharmacotherapy nor biological therapies have disease‐modifying properties. In this context, allergen immunotherapy (AIT) represents an indispensable component of the therapeutic arsenal against allergic asthma, due to its disease‐modifying immunological effects. In this review article, funded by an AIT manufacturer, we find clinical trials support AIT as the only treatment option able both to improve allergic asthma symptoms and to prevent the onset and worsening of the condition. For patients with severe asthma or other safety concerns, the combination of AIT and biologics offers very promising new treatment modalities for the management of allergic asthma. Trial Registration: clinicaltrials.gov identifier: NCT06027073
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Innovation & Science Department, Stallergenes Greer, Antony, France.
- Service de Pneumologie et Centre de référence pour les maladies respiratoires rares, Hôpital Bichat, AP-HP Nord-Université Paris Cité, Paris, France.
- CRISALIS F-CRIN Network, Paris, France.
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.
- Department of Respiratory Medicine, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.
- CRISALIS/FCRIN, Toulouse, France.
ORCID profiles: Thierry Batard, Camille Taillé, Laurent Guilleminault, Andrzej Bozek, Véronique Bordas-Le Floch, Oliver Pfaar, Walter G Canonica, Cezmi Akdis, Mohamed H Shamji, Laurent Mascarell
Funding
- Stallergenes Greer
Cite
APA
Batard, T., Taillé, C., Guilleminault, L., Bozek, A., Floch, V. B., Pfaar, O., Canonica, W. G., Akdis, C., Shamji, M. H., & Mascarell, L. (2025). Allergen Immunotherapy for the Prevention and Treatment of Asthma. Clinical & Experimental Allergy, 55(2), 111-141. https://doi.org/10.1111/cea.14575
Vancouver
Batard T, Taillé C, Guilleminault L, Bozek A, Floch VB, Pfaar O, et al. Allergen Immunotherapy for the Prevention and Treatment of Asthma. Clinical & Experimental Allergy. 2025;55(2):111-141. doi:10.1111/cea.14575
BibTeX
@article{Batard2025,
author = {Batard, Thierry and Taillé, Camille and Guilleminault, Laurent and Bozek, Andrzej and Floch, Véronique Bordas-Le and Pfaar, Oliver and Canonica, Walter G and Akdis, Cezmi and Shamji, Mohamed H and Mascarell, Laurent},
title = {Allergen Immunotherapy for the Prevention and Treatment of Asthma},
journal = {Clinical & Experimental Allergy},
year = {2025},
volume = {55},
number = {2},
pages = {111--141},
doi = {10.1111/cea.14575}
}
EUVIMED